References
- Acter T, Uddin N, Das J, Akhter A, Choudhury TR, Kim S. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: a global health emergency. Sci Total Environ 2020;730:138996.
- Shafieipour S, Rezaei Zadeh Rukerd M, Shamsizadeh Meymandi T, et al. The effect of intravenous tocilizumab therapy on the prognosis of patients with COVID-19: a case-control study. Iran J Med Microbiol 2023;17:243-50. https://doi.org/10.30699/ijmm.17.2.243
- Haghpanah F, Lin G, Levin SA, Klein E. Analysis of the potential impact of durability, timing, and transmission blocking of COVID-19 vaccine on morbidity and mortality. EClinicalMedicine 2021;35:100863.
- Russell FM, Greenwood B. Who should be prioritised for COVID-19 vaccination? Hum Vaccin Immunother 2021;17:1317-21. https://doi.org/10.1080/21645515.2020.1827882
- Bottcher K, Pinzani M. Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents. Adv Drug Deliv Rev 2017;121:3-8. https://doi.org/10.1016/j.addr.2017.05.016
- Ye F, Zhai M, Long J, et al. The burden of liver cirrhosis in mortality: results from the global burden of disease study. Front Public Health 2022;10:909455.
- Zahedi MJ, Shafieipour S, Hayatbakhsh Abbasi MM, et al. Mortality trends of gastrointestinal, liver, and pancreaticcobiliary diseases: a hospital-based prospective study in the southeast of Iran. Middle East J Dig Dis 2022;14:404-9. https://doi.org/10.34172/mejdd.2022.301
- Cabibbo G, Rizzo GE, Stornello C, Craxi A. SARS-CoV-2 infection in patients with a normal or abnormal liver. J Viral Hepat 2021;28:4-11. https://doi.org/10.1111/jvh.13440
- Khamees A, Bani-Issa J, Zoubi MS, et al. SARS-CoV-2 and coronavirus disease mitigation: treatment options, vaccinations and variants. Pathogens 2022;11:275.
- Shaik RA, Ahmad MS, Alzahrani M, et al. Comprehensive highlights of the universal efforts towards the development of COVID-19 vaccine. Vaccines (Basel) 2022;10:1689.
- Forni G, Mantovani A; COVID-19 Commission of Accademia Nazionale dei Lincei, Rome. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ 2021;28:626-39. https://doi.org/10.1038/s41418-020-00720-9
- Dagan N, Barda N, Biron-Shental T, et al. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nat Med 2021;27:1693-5. https://doi.org/10.1038/s41591-021-01490-8
- Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet 2021;397:1725-35. https://doi.org/10.1016/S0140-6736(21)00790-X
- Ayenigbara IO, Adegboro JS, Ayenigbara GO, Adeleke OR, Olofintuyi OO. The challenges to a successful COVID-19 vaccination programme in Africa. Germs 2021;11:427-40. https://doi.org/10.18683/germs.2021.1280
- Cornberg M, Buti M, Eberhardt CS, Grossi PA, Shouval D. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J Hepatol 2021;74:944-51. https://doi.org/10.1016/j.jhep.2021.01.032
- Thuluvath PJ, Robarts P, Chauhan M. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases. J Hepatol 2021;75:1434-9. https://doi.org/10.1016/j.jhep.2021.08.008
- Wells GA, Shea B, O'connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses [Internet]. Burlington (MA): Science-Open; 2015 [cited 2023 May 18]. Available from: https://www.scienceopen.com/document?vid=54b48470-4655-4081-b5d4-e8ebe8d1792e
- Ivashkin V, Ismailova A, Dmitrieva K, et al. Efficacy and safety of COVID-19 vaccination in patients with cirrhosis. World J Hepatol 2022;14:1470-9. https://doi.org/10.4254/wjh.v14.i7.1470
- Wang J, Zhang Q, Ai J, et al. Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study. Hepatol Int 2022;16:691-701. https://doi.org/10.1007/s12072-022-10332-9
- Ruether DF, Schaub GM, Duengelhoef PM, et al. SARSCoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients. Clin Gastroenterol Hepatol 2022;20:162-72. https://doi.org/10.1016/j.cgh.2021.09.003
- Bakasis AD, Bitzogli K, Mouziouras D, et al. Antibody responses after SARS-CoV-2 vaccination in patients with liver diseases. Viruses 2022;14:207.
- Goel A, Verma A, Tiwari P, et al. Serological immune response following ChAdOx1 nCoV-19 vaccine (Covishield(R)) in patients with liver cirrhosis. Vaccines (Basel) 2022;10:1837.
- Diaz LA, Fuentes-Lopez E, Lazo M, Kamath PS, Arrese M, Arab JP. Vaccination against COVID-19 decreases hospitalizations in patients with cirrhosis: results from a nationwide analysis. Liver Int 2022;42:942-4. https://doi.org/10.1111/liv.15193
- Willuweit K, Frey A, Passenberg M, et al. Patients with liver cirrhosis show high immunogenicity upon COVID-19 vaccination but develop premature deterioration of antibody titers. Vaccines (Basel) 2022;10:377.
- Singh A, De A, Singh MP, et al. Antibody response and safety of ChAdOx1-nCOV (Covishield) in patients with cirrhosis: a cross-sectional, observational study. Dig Dis Sci 2023;68:676-84. https://doi.org/10.1007/s10620-022-07641-2
- Giambra V, Piazzolla AV, Cocomazzi G, et al. Effectiveness of booster dose of anti SARS-CoV-2 BNT162b2 in cirrhosis: longitudinal evaluation of humoral and cellular response. Vaccines (Basel) 2022;10:1281.
- Stroffolini T, Ciancio A, Federico A, et al. COVID-19 vaccination among cirrhotics in Italy: high coverage and effectiveness of 3 doses versus 2 in preventing breakthrough infection and hospitalization. Dig Liver Dis 2023;55:316-21. https://doi.org/10.1016/j.dld.2022.11.016
- Iavarone M, Tosetti G, Facchetti F, et al. Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: a prospective single center study. Dig Liver Dis 2023;55:160-8. https://doi.org/10.1016/j.dld.2022.09.010
- Geerling E, Hameed M, Weger-Lucarelli J, Pinto AK. Metabolic syndrome and aberrant immune responses to viral infection and vaccination: Insights from small animal models. Front Immunol 2022;13:1015563.
- Wu Q, Dudley MZ, Chen X, et al. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med 2021;19:173.
- Cao Z, Zhang C, Zhao S, et al. COVID-19 vaccines in patients with decompensated cirrhosis: a retrospective cohort on safety data and risk factors associated with unvaccinated status. Infect Dis Poverty 2022;11:56.
- Luo D, Chen X, Du J, et al. Immunogenicity of COVID-19 vaccines in chronic liver disease patients and liver transplant recipients: a systematic review and meta-analysis. Liver Int 2023;43:34-48. https://doi.org/10.1111/liv.15403
- Li J, Ayada I, Wang Y, et al. Factors associated with COVID-19 vaccine response in transplant recipients: a systematic review and meta-analysis. Transplantation 2022;106:2068-75. https://doi.org/10.1097/TP.0000000000004256